Bloodborne Pathogen Screening (HIV, Hepatitis)

Bloodborne pathogen screening is the testing of asymptomatic people for infections transmitted through blood and body fluids — chiefly HIV and the hepatitis B and C viruses — so that long-silent infections can be detected and acted on. Because these infections can persist for years without symptoms while remaining transmissible and causing progressive organ damage, screening is a core preventive activity in primary care and public health.

Definition

Bloodborne pathogen screening is the application of serologic or virologic tests to asymptomatic individuals to detect infection with bloodborne viruses such as HIV, hepatitis B virus, and hepatitis C virus, as a form of secondary prevention.

Scope

This topic covers the rationale and structure of screening for the major bloodborne viruses: why infection is sought in asymptomatic people, the broad testing strategies (antibody and combined antigen-antibody assays for HIV, surface-antigen and antibody testing for hepatitis B, antibody screening with confirmatory nucleic-acid testing for hepatitis C), and the move toward broad rather than purely risk-based screening. It treats screening as a reference concept and does not prescribe whom to test or how to manage infection, which are set by current guidelines.

Core questions

• Why are HIV and the hepatitis B and C viruses suitable targets for screening asymptomatic people?
• What testing strategies are used to screen for and confirm each of these infections?
• How has screening shifted from purely risk-based to broader population-based approaches?
• How does early detection benefit both the individual and the prevention of transmission?

Key concepts

• Chronic asymptomatic infection
• HIV antigen-antibody (combination) assays
• Hepatitis B surface antigen (HBsAg) testing
• Hepatitis C antibody screening with confirmatory RNA testing
• Universal versus risk-based screening
• Window period
• Linkage to care

Mechanisms

HIV and the hepatitis B and C viruses can establish chronic infection that remains asymptomatic for years while continuing to be transmissible and, for the hepatitis viruses, progressing toward cirrhosis and liver cancer. Screening detects these silent infections by identifying viral antigens, host antibodies, or viral nucleic acid in blood. HIV screening commonly uses combination antigen-antibody immunoassays that shorten the window period after infection; hepatitis B screening centres on the surface antigen; and hepatitis C screening uses an antibody test followed by confirmatory nucleic-acid testing to distinguish current from past infection. Detecting infection early enables linkage to effective treatment and, by reducing infectiousness, supports prevention of onward transmission. Because much transmission arises from people unaware of their status, the field has moved toward broader, less stigmatising screening.

Clinical relevance

Recommendations for bloodborne pathogen screening determine which patients are offered HIV and hepatitis testing in routine care, and understanding the testing strategies supports appraisal of those recommendations. This entry describes the purpose and basis of screening as a preventive activity; decisions about whom to test, how to interpret a reactive result, and how to manage infection are governed by current clinical guidelines and are outside its scope.

Epidemiology

HIV and chronic hepatitis B and C together affect hundreds of millions of people worldwide and cause substantial mortality, much of it through liver disease and AIDS-related illness, and a large share of those infected are undiagnosed. This undiagnosed reservoir is the central justification for broad screening, and recommendations increasingly favour at least one-time screening of adults for these infections in addition to risk-based and repeat testing; the specific recommendations are set out in the cited guidelines.

History

Screening for bloodborne viruses began with the protection of the blood supply after hepatitis B surface antigen and then HIV antibody tests became available in the 1970s and 1980s, and was later extended to routine clinical screening. Hepatitis C testing followed the virus's identification in 1989. Over subsequent decades, guidance shifted from narrowly risk-based testing toward recommending broad, often one-time, screening of adults for HIV and the hepatitis viruses, reflecting the large undiagnosed burden and the availability of effective treatment.

Debates

Risk-based versus universal screening

Screening confined to recognised risk groups misses many infected people who do not report risk factors, which has driven a shift toward broader age-based or one-time universal screening for HIV and the hepatitis viruses; the balance between targeted and universal approaches continues to be refined in guidelines.

Seminal works

• uspstf-hiv-2019
• uspstf-hcv-2020
• uspstf-hbv-2020

Frequently asked questions

Why is broad screening recommended for HIV and hepatitis rather than testing only high-risk people?

Many people with these infections do not report recognised risk factors, so risk-based testing alone misses a large number of cases; broad or one-time screening of adults detects more infections early, when treatment is most effective.

How is hepatitis C screening confirmed?

Hepatitis C screening starts with an antibody test; because antibodies can persist after a cleared infection, a reactive result is confirmed with a nucleic-acid (RNA) test to determine whether the infection is current.